Literature DB >> 20971177

pH-sensitive Eudragit nanoparticles for mucosal drug delivery.

Jin-Wook Yoo1, Namita Giri, Chi H Lee.   

Abstract

Drug delivery via vaginal epithelium has suffered from lack of stability due to acidic and enzymatic environments. The biocompatible pH-sensitive nanoparticles composed of Eudragit S-100 (ES) were developed to protect loaded compounds from being degraded under the rigorous vaginal conditions and achieve their therapeutically effective concentrations in the mucosal epithelium. ES nanoparticles containing a model compound (sodium fluorescein (FNa) or nile red (NR)) were prepared by the modified quasi-emulsion solvent diffusion method. Loading efficiencies were found to be 26% and 71% for a hydrophilic and a hydrophobic compound, respectively. Both hydrophilic and hydrophobic model drugs remained stable in nanoparticles at acidic pH, whereas they are quickly released from nanoparticles upon exposure at physiological pH. The confocal study revealed that ES nanoparticles were taken up by vaginal cells, followed by pH-responsive drug release, with no cytotoxic activities. The pH-sensitive nanoparticles would be a promising carrier for the vaginal-specific delivery of various therapeutic drugs including microbicides and peptides/proteins. Published by Elsevier B.V.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20971177     DOI: 10.1016/j.ijpharm.2010.10.032

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  32 in total

1.  Influence of some formulation variables on the optimization of pH-dependent, colon-targeted, sustained-release mesalamine microspheres.

Authors:  Ahmed Abd El-Bary; Ahmed A Aboelwafa; Ibrahim M Al Sharabi
Journal:  AAPS PharmSciTech       Date:  2011-12-01       Impact factor: 3.246

2.  Hollow microspheres for gastroretentive floating- pulsatile drug delivery: preparation and in vitro evaluation.

Authors:  Maryam Maghsoodi; Elham Hemati; Bahram Qadermazi; Zahra Yari
Journal:  Adv Pharm Bull       Date:  2011-12-15

Review 3.  A review of nanotechnological approaches for the prophylaxis of HIV/AIDS.

Authors:  Abhijit A Date; Christopher J Destache
Journal:  Biomaterials       Date:  2013-05-28       Impact factor: 12.479

4.  Treatment of blood flow abnormality using mucosal delivery of nitric oxide.

Authors:  Chi H Lee
Journal:  Drug Deliv Transl Res       Date:  2011-06       Impact factor: 4.617

5.  Nanoparticle-releasing nanofiber composites for enhanced in vivo vaginal retention.

Authors:  Emily A Krogstad; Renuka Ramanathan; Christina Nhan; John C Kraft; Anna K Blakney; Shijie Cao; Rodney J Y Ho; Kim A Woodrow
Journal:  Biomaterials       Date:  2017-08-01       Impact factor: 12.479

Review 6.  Recent advances in oral vaccine development: yeast-derived β-glucan particles.

Authors:  Rebecca De Smet; Liesbeth Allais; Claude A Cuvelier
Journal:  Hum Vaccin Immunother       Date:  2014-02-19       Impact factor: 3.452

7.  Pharmaceutically Acceptable Carboxylic Acid-Terminated Polymers Show Activity and Selectivity against HSV-1 and HSV-2 and Synergy with Antiviral Drugs.

Authors:  Tejabhiram Yadavalli; Sudipta Mallick; Pratikkumar Patel; Raghuram Koganti; Deepak Shukla; Abhijit A Date
Journal:  ACS Infect Dis       Date:  2020-10-20       Impact factor: 5.084

8.  Sustained-release Griffithsin nanoparticle-fiber composites against HIV-1 and HSV-2 infections.

Authors:  Kevin M Tyo; Amanda B Lasnik; Longyun Zhang; Mohamed Mahmoud; Alfred B Jenson; Joshua L Fuqua; Kenneth E Palmer; Jill M Steinbach-Rankins
Journal:  J Control Release       Date:  2020-02-05       Impact factor: 9.776

9.  Thermosensitive hydrogel of hydrophobically-modified methylcellulose for intravaginal drug delivery.

Authors:  Ning Li; Meihua Yu; Liandong Deng; Jun Yang; Anjie Dong
Journal:  J Mater Sci Mater Med       Date:  2012-05-09       Impact factor: 3.896

10.  Nanofiber-coated drug eluting stent for the stabilization of mast cells.

Authors:  Byeongtaek Oh; Chi H Lee
Journal:  Pharm Res       Date:  2014-03-25       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.